Results 211 to 220 of about 68,843 (264)

Haemophilus influenzae Type b

1991
Invasive disease caused by Haemophilus influenzae type b (Hib) is recognized as a leading infectious disease health problem, primarily for young children (Table 1). An estimated 20,000 persons develop invasive Hib disease each year in the United States, and it has also been estimated that during the first 5 years of life the cumulative incidence of ...
Stephen L. Cochi, Joel I. Ward
openaire   +1 more source

Haemophilus Influenza Type b

Disease-a-Month, 2007
Susan Shoshana Weisberg, MD, FCP, FAAP aemophilus influenza type b is best known by its nickname, Hib. The influenza” in Hib’s formal name is actually a mistake. The Hib germ was rst discovered in 1892, in the middle of a flu epidemic, and it was first solated from the saliva of patients suffering from influenza.
openaire   +1 more source

Haemophilus influenzae type b conjugate vaccine

Journal of Pediatric Health Care, 1988
Abstract Hib conjugate vaccine was developed with the ultimate goal of providing an effective vaccine for infants and younger children. The conjugate vaccine is as safe as Hib polysaccharide vaccine and significantly more immunogenic. Because antibody production after vaccination with conjugate vaccine in children 18 months of age or older is ...
J J, Campion, D T, Casto
openaire   +2 more sources

Haemophilus influenzae type b unsuspected bacteremia

Pediatric Emergency Care, 1987
To further define the clinical features and natural history of unsuspected Haemophilus influenzae type b (Hib) bacteremia, we retrospectively reviewed the records of 322 Hib infections observed during a 45-month period at Children's Hospital, Boston. We identified 31 patients with unsuspected Hib bacteremia and 19 with unsuspected Hib antigenemia and ...
A B, Anderson, D M, Ambrosino, G R, Siber   +2 more
openaire   +2 more sources

Haemophilus influenzae Type b Conjugate Vaccines

1995
In summary, all of the Hib conjugate vaccines are highly immunogenic and efficacious in children older than 12-15 months of age, and HbOC, PRP-OMPC, and PRP-T are highly immunogenic and demonstrated to be efficacious in infants as young as 2 months old.
P J, Kniskern, S, Marburg, R W, Ellis
openaire   +2 more sources

Haemophilus Influenzae Type B (Hib)

2018
All infants without contraindications should receive the conjugate Hib vaccine series; either as 3 doses of PRP-OMP (trade name: PedvaxHIB®), or as 4 doses of PRP-T (trade names: ActHIB®, Hiberix®; also included in the DTaP-Hib-IPV combination vaccine Pentacel®).
Matthew Z. Dudley, Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O’Leary, Saad B. Omer   +6 more
openaire   +1 more source

Haemophilus influenzae type b vaccination

The Lancet, 1997
A, Melhus, A, Hemansson
openaire   +3 more sources

HAEMOPHILUS INFLUENZAE NON TYPE b

The Lancet, 1985
R A, Wall, D C, Mabey, P T, Corrah
openaire   +2 more sources

Haemophilus influenzae Type b Disease

JAMA, 1977
Haemophilus influenzae type b (HIB) disease was observed during a 14-month period in seven of 48 infants attending a day-care center. Surveillance studies showed that 28 (58%) infants had positive nasopharyngeal cultures for HIB; four infants were colonized with HIB for nine to 12 months.
openaire   +1 more source

[Haemophilus influenzae type b vaccine].

Nihon rinsho. Japanese journal of clinical medicine, 2011
Haemophilus influenzae type b (Hib) vaccine has been included in the national Immunization Program in more than 120 countries around the world and its effectiveness and safety have been confirmed. In Japan, Hib vaccine was recently licensed in December 2008.
Tomohiro, Katsuta, Akihiko, Saitoh
openaire   +1 more source